BioWorld

May 29, 2009

View Archived Issues

Exelixis Shares Soar on $1B Cancer Drug Deal with Sanofi

If all goes according to plan, Exelixis Inc. could bank more than $1 billion under a new licensing and discovery deal with Sanofi-Aventis Group for phosphoinositide-3 kinase (PI3K) inhibitors targeting cancer. (BioWorld Today) Read More

Phase II Trial Update Triggers Wild Ride for Peregrine Shares

Read More

'Finished' Mouse Genome Is Still a Work in Progress

Read More

As Markets Brighten, Medivation Seeks $65.8M in Shares Offering

Read More

Neuropharm Revives Autism Drug, Rises on Partner Talks

Read More

Amylin 'Back to Business' Following Contentious Vote

Read More

Other News To Note

Read More

Clinic Roundup

Read More